RESULTS : Twenty cases were included. Males and small breed dogs were over-represented. Frequent clinical signs included weight loss, vomiting and diarrhoea. Most lymphomas were T-cell phenotype (95%), and epitheliotropism was commonly described (60%). Immunohistochemistry, polymerase chain reaction for antigen receptor rearrangement or both were frequently required for definitive diagnosis. Two dogs had resection of an intestinal mass, and all dogs were treated with chemotherapy; chlorambucil and prednisone were most commonly prescribed. Overall response rate was 70%, and median survival time was 424 days (95% confidence interval: 105 to 1206 days).
INTRODUCTION
Gastrointestinal lymphoma represents 5% to 7% of all lymphomas in dogs. Most dogs are presented with the disease confined to the gastrointestinal tract, with a minority displaying multicentric involvement (Couto et al . 1989 , Rassnick et al . 2009 ). A higher frequency in male dogs was reported in one study (Couto et al . 1989 ) , while others have found no gender predilection (Frank et al . 2007 , Rassnick et al . 2009 ). Breed predispositions have been suggested in shar-peis and boxers (Coyle & Steinberg 2004 ) . Among lymphomas of the small intestinal tract, the T-cell phenotype is most common, and epitheliotropism is commonly identified on histopathology (Steinberg et al . 1995 , Coyle & Steinberg 2004 ).
In most reported cases, primary gastrointestinal lymphoma in dogs is of a large cell and high grade type, with small-cell, low-grade lymphomas of the canine gastrointestinal tract rarely described (Couto et al . 1989 , Ozaki et al . 2006 , Carrasco et al . 2015 , Nakashima et al . 2015 . Several studies have evaluated treatment and response in dogs with high-grade gastrointestinal lymphoma. The prognosis with an injectable multi-agent chemotherapy protocol is reported to be poor, with median survival time (MST) ranging from 13 to 77 days (Frank et al . 2007 , Rassnick et al . 2009 ). In one study, dogs with diarrhoea had a worse prognosis as compared to those without (Rassnick et al . 2009 ). The survival time for dogs with low-grade gastrointestinal lymphoma is reported to be much better than the high-grade form (Nakashima et al . 2015 ) , but it is not well-studied.
The primary objective of this study was to describe the clinical presentation and treatment of dogs with histologically confirmed low-grade gastrointestinal lymphoma. A secondary objective was to identify prognostic factors influencing progression-free survival and overall survival time.
MATERIALS AND METHODS
The American College of Veterinary Internal Medicine Oncology Diplomate listserv was solicited to recruit cases for this retrospective study. Medical records of dogs with a diagnosis of low-grade gastrointestinal lymphoma [via a combination of histology and immunohistochemistry (IHC), polymerase chain reaction for antigen receptor rearrangement (PARR) or both] were included. Records of dogs diagnosed between 2010 and 2016 at contributing institutions were retrospectively reviewed.
Information gathered from the medical record included signalment, weight, dates of diagnosis and treatment initiation, presenting clinical signs, duration of clinical signs, previous treatments, concurrent diseases, physical examination findings, laboratory test results (including complete blood count, serum chemistry, urinalysis, folate, cobalamin, trypsin-like immunoreactivity, pancreatic lipase immunoreactivity levels and faecal analysis when available), imaging findings (thoracic radiographs and abdominal ultrasound), method of biopsy (endoscopic or full-thickness), sites biopsied, IHC and results of PARR testing, location of lymphoma within the gastrointestinal tract, chemotherapy protocol, response to treatment, date of first progression, rescue therapies and date and cause of death or last follow-up visit. Results of laboratory testing were classified as normal or abnormal by comparing results to the established reference interval for that particular facility. Biopsy samples were not re-evaluated.
Response to treatment was reported by the veterinarian and, in most cases, was determined by monitoring of clinical signs. In some cases, follow-up abdominal imaging was also assessed. In cases evaluated by monitoring of clinical signs alone, complete response (CR) was defined as resolution of all clinical signs ( i.e. vomiting, diarrhoea, weight loss), partial response (PR) was defined as improvement but not resolution of clinical signs for a minimum of 6 weeks, and no response (NR) was defined as no improvement in clinical signs. For patients with an initial response to treatment, progressive disease (PD) was defined as relapse or worsening of clinical signs. Among patients evaluated with recheck abdominal ultrasound, response [CR, PR, stable disease (SD) and PD] was classified using Veterinary Cooperative Oncology Group criteria (Nguyen et al . 2013 ) .
Categorical data are presented as either percentages or ratios. Continuous data are presented as median (range). Progressionfree survival (PFS) was defined as the time from initiation of treatment until recurrence or progression of clinical signs consistent with lymphoma. Dogs that had not relapsed during the study period were censored at the last date they were evaluated by the veterinarian. Survival time was defined as the time from the initiation of treatment until natural death or euthanasia. Dogs that were lost to follow-up or were still alive at the end of the study period were censored. All deaths were attributed to lymphoma because post mortem examination was not performed in any case.
Survival analysis was performed using the Kaplan-Meier product limit method to estimate median PFS and MST. Using univariate analysis, potential prognostic factors were analysed to determine their effect on PFS and MST. These included gender, weight, clinical signs (presence of vomiting, diarrhoea and weight loss), duration of clinical signs, pretreatment with steroids, hypoalbuminaemia and initial treatment with chlorambucil and a glucocorticoid versus other forms of chemotherapy. The log-rank test was used to compare survival distributions for PFS and MST between factors. Due to the small number of dogs in each group and high number of dogs that were censored, multi-variate analysis was not performed. A value of P 0·05 was considered significant. Calculations were performed using standard statistical software (SAS version 9.4 for Windows).
RESULTS
Twenty dogs were included in the study. Table 1 summarises signalment, clinical signs and pretreatment diagnostics. There were 13 neutered males (65%) and seven spayed females (35%). The median age at presentation was 9·5 years (range: 4·2 to 15·1 years), and the median weight was 9·9 kg (range: 3·7 to 44 kg). The majority of dogs (19/20; 95%) showed clinical signs at the time of presentation, and the median duration of clinical signs before presentation was 54 days (range: 1 to 420 days) for the 18 dogs in which this information was recorded.
Two dogs (10%) had a history of chronic enteropathy: lymphangiectasia in Case 17 (diagnostic method not recorded) and inflammatory bowel disease in Case 19 (diagnosed as lymphoplasmacytic enteritis via endoscopic biopsies). Concurrent diseases were diagnosed in three dogs (15%) at the time of diagnosis of low-grade gastrointestinal lymphoma and included chronic lymphocytic leukaemia (Case 19), splenic marginal zone lymphoma (Case 4) and a high-grade soft-tissue sarcoma (which was treated with surgical excision) (Case 8).
Four dogs (four of 20; 20%) had been previously treated with corticosteroids. Case 19 had been on long-term 1 mg/ kg prednisone once daily for previously diagnosed conditions (hypoadrenocorticism and inflammatory bowel disease). The remaining three dogs (Cases 1, 2 and 20, respectively) had received a steroid trial (1 mg/kg once daily tapered over 2 weeks, 1 mg/kg once daily for 5 months and 0·5 mg/kg once daily for 1 month) before diagnosis of low-grade gastrointestinal lymphoma, and clinical signs persisted with no apparent response to corticosteroids in all three dogs. Frequently observed abdominal ultrasound abnormalities included thickening of the muscularis layer of the small intestinal wall (six of 18; 33·3%), mesenteric lymphadenomegaly (five of 18; 27·8%) and a splenic mass or nodule (four of 18; 22·2%). Enlarged mesenteric lymph nodes were sampled via fine-needle aspiration in two dogs; cytology was consistent with lymphoid neoplasia in Case 1 and hyperplasia in Case 8.
Histopathological samples were obtained in all dogs either via laparotomy (11/20; 55%) or endoscopy (nine of 20; 45%). In addition to the acquisition of full-thickness gastrointestinal biopsies, additional procedures in dogs undergoing laparotomy included resection and anastomosis of a mass affecting the intestine (two of 11; 18·2%) and splenectomy (two of 11; 18·2%). Of the dogs that underwent endoscopy, most procedures evaluated the upper gastrointestinal tract only (7/9; 77·8%), while two dogs had both upper and lower endoscopy (2/9; 22·2%). No complications associated with laparotomy or endoscopy were reported. Tables 2 and 3 summarise the findings in patients undergoing laparotomy and endoscopy, respectively.
Chemotherapeutic protocols varied between dogs. Most dogs were treated with chlorambucil and a glucocorticoid (15/20; 75%). The median dose was 5 mg/m 2 chlorambucil once every 24 to 48 hours (range of 1·8 to 8 mg/m 2 once every 24 to 48 hours). Chemotherapeutic protocols and response are summarised in Table 4 . Six dogs were re-evaluated by abdominal ultrasound after therapy was initiated. CR with resolution of intestinal thickening and lymphadenomegaly was observed in two dogs (Cases 13 and 16). In Case 18, no abnormalities were seen on abdominal ultrasound before or after initiating chemotherapy, but clinical signs in this dog completely resolved. In the two dogs (Cases 7 and 8) that had undergone resection and anastomosis of an intestinal mass, both had no abnormalities found on postoperative imaging, including resolution of mesenteric lymphadenomegaly in Case 8. In Case 14, PD was noted 6 weeks after starting lomustine and prednisone therapy. Overall, five of six (83·3%) dogs undergoing recheck abdominal ultrasound responded to treatment. Among the 14 dogs for which response was evaluated based on clinical signs alone, complete resolution of clinical signs was noted in seven dogs (50%) and partial resolution in two dogs (14·3%) for an overall response rate of 64·3%. In five dogs, there was no clinical response to initial therapy. Rescue protocols and response are also summarised in Table 4 . At the end of the study period, eight dogs were still alive (40%), 12 dogs died or were euthanased with clinical signs attributed to lymphoma (60%), and no dogs were lost to followup. Post mortem examination was not performed on any dog. The median follow-up time was 285 days (range: 122 to 1404 days). The overall MST was 424 days [95% confidence interval (CI): 105 to 1206 days] (Fig 1 ) . The 1-year survival rate was 55%. Dogs achieving CR or PR had an MST of 535 days (95% CI: 172 to 1206 days), while dogs with NR to chemotherapy had an MST of 92 days (95% CI: 14 to 537 days).
On univariate analysis of this small sample population, there was no statistically significant association between any of the evaluated factors (gender, weight, presence of vomiting, diarrhoea or weight loss, duration of clinical signs, pretreatment with steroids, hypoalbuminemia, initial treatment with chlorambucil and a glucocorticoid versus other forms of chemotherapy) and either median PFS or MST.
DISCUSSION
The objective of the current study was to describe the clinical presentation, treatment and prognosis in dogs with low-grade gastrointestinal lymphoma. This form of gastrointestinal lymphoma occurs over a wide age range (4·2 to 15·1 years), and small dogs (median weight of 9·9 kg) appeared to be over-represented in this study, although the comparator population against which to judge this is not well defined. As has been suggested for high-grade gastrointestinal lymphoma in dogs (Couto et al . 1989 ) , male dogs might be predisposed to low-grade gastrointestinal lymphoma, with a male: female ratio in the current study of 1·9:1. The majority of dogs presented with clinical signs of gastrointestinal disease, with weight loss, vomiting and diarrhoea Dogs still alive at the end of the study period were censored. All deaths were attributed to lymphoma as a post mortem examination was not performed in any case. The median survival time was 424 days (95% confidence interval: 105 to 1206 days). Solid circles represent censored dogs most commonly reported. Results of this study also suggest that low-grade gastrointestinal lymphoma in dogs is typically T-cell in phenotype and often exhibits epitheliotropism. Unlike high-grade gastrointestinal lymphoma in dogs, which is associated with a short response duration to chemotherapy and survival times of 13 days to 77 days (Frank et al . 2007 , Rassnick et al . 2009 ), most dogs with low-grade gastrointestinal lymphoma appear to have a positive response to chemotherapy (70% overall response rate) with a MST of 535 days in dogs responding to treatment. Overall MST in this study, including dogs that did not respond to their initial treatment protocol, was 424 days.
In this patient population, biopsy samples were obtained via laparotomy in 11 dogs and via endoscopy in nine dogs, seven of which had upper endoscopy alone. Studies in cats with lowgrade gastrointestinal lymphoma and in dogs with chronic gastrointestinal signs have demonstrated that full-thickness biopsies might be superior to endoscopically-obtained biopsies to obtain adequate tissue samples to reach a definitive diagnosis (Evans et al . 2006 , Scott et al . 2011 . In cats, sampling of the ileum can be critical in some cases to obtain a diagnosis of low-grade gastrointestinal lymphoma (Kleinschmidt et al . 2006 ) . Additionally, the importance of ileal sampling has been demonstrated in dogs with chronic small intestinal enteropathies (Procoli et al . 2013 ). In the current study, low-grade gastrointestinal lymphoma was diagnosed in various portions of the gastrointestinal tract, ranging from the stomach to the ileum. In three dogs (27·3%) that underwent laparotomy, only samples from the ileum were confirmatory for lymphoma, further suggesting that ileal sampling might also be critical in dogs. Given this finding, it is possible that the diagnosis of low-grade gastrointestinal lymphoma might be overlooked if patients undergo upper endoscopy alone. Ileal sampling may be achieved via laparotomy, laparoscopy or by performing both upper and lower gastrointestinal endoscopy.
While all dogs in the current study were ultimately confirmed to have low-grade gastrointestinal lymphoma, the initial histopathology was not always definitive for lymphoma. In eight dogs (40%; six dogs that underwent surgical biopsies and two dogs that underwent endoscopic biopsies), the diagnosis was confirmed on initial evaluation of the biopsy, while in the remaining 12 dogs (60%; five dogs that underwent surgical biopsies and seven dogs that underwent endoscopic biopsies), histopathology indicated lymphocytic enteritis with possible or suspected lymphoma. In these dogs, the diagnosis of low-grade gastrointestinal lymphoma was established with IHC and, in seven of these 12 dogs, the diagnosis was further confirmed with a monoclonal neoplastic cell population identified on PARR analysis. In two cases, the pathologist reported that IHC enabled the identification of clusters of T-cells within the mucosa that were not recognised on routine examination. As has been suggested in previous studies of canine gastrointestinal lymphoma (Carrasco et al . 2015 , Nakashima et al . 2015 and in a study of low-grade gastrointestinal lymphoma in cats (Kiupel et al . 2011 ), these findings indicate that IHC, PARR or both are often necessary to differentiate lymphocytic inflammation from low-grade lymphoma in cases of chronic enteropathy in dogs. Development of standardised histological criteria and a routine diagnostic algorithm for canine intestinal biopsies is recommended to ensure that a diagnosis of low-grade lymphoma is not overlooked.
Interestingly, three of the 20 dogs in the current study had a gastrointestinal mass (one gastric mass, one jejunal mass and one mass at the jejunoileal junction). The dog with the gastric mass underwent superficial endoscopic biopsy only, but both the jejunal and jejunoileal masses were histologically confirmed to be a transmural low-grade gastrointestinal lymphoma. In cats with gastrointestinal lymphoma, transmural lymphomas are typically associated with a large-cell, high-grade phenotype (Moore et al . 2012 ) . While focal transmural intestinal masses have occasionally been described in cats with low-grade gastrointestinal lymphoma (Lingard et al . 2009 ), our findings may suggest that this is a more common phenomenon in dogs with this disease.
Two dogs in this study had additional lymphoid neoplasms identified at the time of their lymphoma diagnosis, chronic lymphocytic leukaemia (Case 19) and splenic marginal zone lymphoma (Case 4). The documentation of additional low-grade lymphoid malignancies raises the question of whether these cancers may be related within the patient. In both cases, the lowgrade gastrointestinal lymphoma was confirmed to be T-cell on IHC. Flow cytometry in Case 19 confirmed T-cell leukaemia, and therefore, it is possible that these circulating lymphocytes represent an extension of gastrointestinal lymphoma. In Case 4, however, IHC of the spleen after splenectomy confirmed a B-cell marginal zone lymphoma, and therefore, two separate lymphoid malignancies were suspected in this case.
A large number of dogs (50%) in this study were hypoalbuminaemic at presentation. This highlights the importance of considering low-grade gastrointestinal lymphoma as a differential diagnosis in dogs with protein-losing enteropathy (PLE), especially if there is a poor response to standard treatment. In one study, a longer clinical response was observed in dogs with PLE treated with a combination of chlorambucil and prednisolone as compared to dogs treated with azathioprine and prednisolone, and the authors proposed that some of these dogs may have had an underlying low-grade lymphoma (Dandrieux et al . 2013 ) . Prospective studies are needed to determine the prevalence of lowgrade gastrointestinal lymphoma in dogs presenting with PLE.
Additionally, hypocobalaminaemia was documented in four of the 10 dogs tested in this current study. As lymphoma in many dogs involved the ileum, decreased absorption of cobalamin and subsequent hypocobalaminaemia might be an important comorbidity. Hypocobalaminaemia is reported to be a negative prognostic factor for the survival in dogs with chronic enteropathies (Allenspach et al . 2007 ) , and therefore, measurement of cobalamin and supplementation if indicated may be an important component of treatment for dogs with low-grade gastrointestinal lymphoma.
There are several limitations to this study based on its multiinstitutional retrospective design and small sample size. In the majority of dogs, response to treatment was based on the monitoring of clinical signs alone. It is important to note that gastrointestinal side effects from chemotherapy may mimic symptoms of progressive gastrointestinal lymphoma, and therefore, assumptions made regarding response to treatment may have been inaccurate. Additionally, there was considerable variability in treatment protocols and frequency of follow-up. Dosing, schedule and duration of chemotherapy were not standardised and varied widely among dogs. Finally, because 40% of the study population was still alive at last follow-up, there was a high degree of censoring, which limits the reliability of statistical analysis and precluded multi-variable analysis. Low-grade gastrointestinal lymphoma appears to be a rare cancer in dogs, but it might be under-recognised. A prospective, multi-institutional study evaluating response to standardised protocols would allow further elucidation of the prevalence of this cancer, prognostic factors and the most effective treatment options.
In conclusion, canine low-grade gastrointestinal lymphoma typically affects small breed, male dogs and is most frequently T-cell in phenotype. Treatment with chemotherapy results in a high response rate and favourable survival times.
